التجارب السريرية بالأسفل التجارب السريرية الحالية.257 دراسات في علم الأورام (طبي) (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to determine the maximum tolerated dose (MTD) of AG-270 and characterize its dose-limiting toxicities (DLTs) when given daily by mouth to subjects with advanced solid tumors or lymphoma with homozygous deletion of methylthioadenosine phosphorylase (MTAP). A Study to Evaluate Immune and Hematopoietic Cell Assessment in Clonal B Cell Conditions Rochester, Minn. The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) in comparison to age-matched healthy control (HC) donors. Database of All Patients with Peritoneal Surface Malignancies Treated at Mayo Clinic Rochester, Minn. The purpose of this study is to: Establish a prospective database of all patients with peritoneal surface malignancies seen by Dr. Travis Grotz at the Mayo Clinic, Rochester. Design and implement quality improvement projects utilizing this database Design and implement outcomes research using this prospective database Design and implement quality of life studies using this prospective database A Phase 1/2 Study Of STP938 For Adult Subjects With Relapsed/Refractory B-Cell And T-Cell Lymphomas Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas. Cerebrospinal Fluid Biomarkers For Brain Tumors Rochester, Minn. The purpose of this study is to help generate a repository of Cerebrospinal Fluid (CSF) samples relevant to neuro-oncology research that may facilitate the identification of biomarkers that are predictive of disease burden, therapeutic susceptibility or response to therapy. This protocol will also provide a vehicle for CSF access for patients or providers wishing to generate or evaluate individualized biomarkers as part of other research or individualized therapy protocols. Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer Scottsdale/Phoenix, Ariz. The purpose of this study is to determine freedom from ipsilateral breast recurrence occurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor at 3 years. Study Of Gastric Cancer And Limited Peritoneal Metastasis Using Robotic Cytoreduction And Hyperthermic Intraperitoneal Chemotherapy Rochester, Minn. The purpose of this study is to assess short-term morbidity and disease-free survival outcomes for patients with gastric adenocarcinoma with limited low volume peritoneal metastasis and/or positive peritoneal cytology undergoing robotic cytoreduction and hyperthermic intraperitoneal chemotherapy. Combination Therapy Of Acalabrutinib, Venetoclax And Durvalumab To Treat Richter Transformation Rochester, Minn. The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter’s transformation, and what doses of these drugs are safe for people to take. We also want to learn about the side effects of this combination. All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung cancers including non-small cell lung cancer and small cell lung cancer. Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn’t approved by the U.S. Food and Drug Administration (FDA). However, the FDA has allowed the use of this drug in this research study. Testing Whether High Dose Chemotherapy And Infusion Of The Patients' Own Stem Cells Improves Survival In Patients With Peripheral T-cell Lymphoma Who Achieved A Complete Response At The End Of The Initial Chemotherapy Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. Usual treatment after a complete response may include observation or high dose chemotherapy followed by an autologous stem cell transplant, however, it is not known if a transplant if beneficial. Giving chemotherapy before a stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Stem cells removed prior to treatment are then returned to the patient to replace the blood forming cells that were destroyed by the chemotherapy. Giving high dose chemotherapy followed by an autologous stem cell transplant may be more effective compared to observation only in treating patients with peripheral T-cell lymphoma who have achieved a complete response after initial chemotherapy. Highly Selective CDK7 Inhibitor Q901 In Selected Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 88 توجّه للصفحة 99 توجّه للصفحة 1010 توجّه للصفحة 1111 توجّه للصفحة 1212 التاليالصفحة التالية طلب تحديد موعد الخبرة و مراتب التصنيفبحث 24/12/2024 صُنفت مايو كلينك في مدينة روتشستر بولاية مينيسوتا ومايو كلينك في جاكسونفيل بولاية فلوريدا ومايو كلينك في فينيكس/سكوتسديل بولاية أريزونا ضمن أفضل المستشفيات لعلاج السرطان على مستوى الولايات المتحدة حسب شبكة U.S. News & World Report. اعرف المزيد عن هذا الشرف الرفيع علم الأورام (طبي)القسمالرئيسيالأقساممُلخّصالحالات التي تم علاجهاالأطباءالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالةالمرضى الأبحاث: المرضى محور اهتمامنا إظهار النسخة النصية للفيديو الأبحاث: المرضى محور اهتمامنا [عزف موسيقي] جوزيف سيرفين، دكتور في الطب، أستاذ طب الأعصاب في مايو كلينك: تتمثّل مهمة مايو في رعاية المريض. فمصلحة المريض أولًا. ولذلك فإن مهمّتنا وأبحاثنا تهدف إلى إحراز التقدّم في طريقة الاعتناء بالمريض، وتقديم مصلحته على كل الجوانب الأخرى من الرعاية. وهذا من عدة أوجه أقرب إلى دورة متعاقبة المراحل. فالأمر يبدأ بفكرة بسيطة ثبت نجاحها في المختبر، ثم طُبِّقت على المريض في سريره، وإذا سار كل شيء على ما يرام -بمعنى أنها كانت مفيدة له- فإننا نعتمدها على أنها نهج قياسي. وهذا في رأيي واحد من السمات الفريدة التي تميّز نهج مايو كلينك في البحث -أعني التركيز على المريض- وهو يساعد بحق في تمييزه عمّا سواه. الأقسامطلب موعدمُلخّصالحالات التي تم علاجهاالأطباءالمجموعات المتخصصةالخبرة و مراتب التصنيفالتجارب السريريةبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالة المرضى ORG-20180179 الأقسام والمراكز الطبية علم الأورام (طبي)